Upfront metastasis-directed therapy in oligorecurrent prostate cancer does not decrease the time from initiation of androgen deprivation therapy to castration resistance.
Triggiani L, Mazzola R, Tomasini D, Bruni A, Alicino G, Matrone F, Bortolus R, Francolini G, Detti B, Magli A, Bonù ML, Ingrosso G, Lancia A, Trippa F, Maranzano E, Franzese C, Ghirardelli P, Vavassori V, Scorsetti M, Alongi F, Magrini SM.
Triggiani L, et al. Among authors: vavassori v.
Med Oncol. 2021 May 18;38(6):72. doi: 10.1007/s12032-021-01518-6.
Med Oncol. 2021.
PMID: 34008151
Free PMC article.